ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

romosozumab

Also written as “Romosozumab”, “Romozosumab” and “romosozumab HCP administration with PFS”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Bone Diseases, Metabolic · Osteogenesis Imperfecta · Hip Fractures, led by 2 companies.

Drug pageRomosozumab: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 25, 202322 company-led studies, 2 open or runningNext primary completion: Jan 14, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only212 open or runningphase 4since Sep 25, 2023May 7, 2009Jan 14, 2027phase 1 · NCT07811999
UCB10 open or runningphase 3since Sep 23, 2021Sep 23, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of UCB only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 23, 2021First study: phase 3 study in OsteoporosisFirst studyNCT05067335 · 327 enrolled · China

TargetBeta

SOST →read by rule
“Sclerostin inhibitor”ChEMBL 37, by rule

Studies

The one study UCB leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05067335Osteoporosis · China3CompletedNov 9, 2023327

How it is read

Names in the registry

  • “Romosozumab”, 19 entries
  • “Romozosumab”, 1 entry
  • “romosozumab HCP administration with PFS”, 1 entry
  • “Romosozumab 90 mg/mL”, 1 entry
  • “Romosozumab 70 mg/mL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.